Nonalcoholic steatohepatitis (NASH) is characterized by hepatic steatosis with inflammation and fibrosis. Membrane endoglin (Eng) expression is shown to participate in fibrosis, and plasma concentrations of soluble endoglin (sEng) are increased in patients with hypercholesterolemia and type 2 diabetes mellitus. We hypothesize that NASH increases both hepatic Eng expression and sEng in blood and that high levels of sEng modulate cholesterol and bile acid (BA) metabolism and affect NASH progression. Three-month-old transgenic male mice overexpressing human sEng and their wild type littermates are fed for six months with either a high-saturated fat, high-fructose high-cholesterol (FFC) diet or a chow diet. Evaluation of NASH, Liquid chromatography-mass spectrometry (LC/MS) analysis of BA, hepatic expression of Eng, inflammation, fibrosis markers, enzymes and transporters involved in hepatic cholesterol and BA metabolism are assessed using Real-Time Quantitative Reverse Transcription Polymerase Chain reaction (qRT-PCR) and Western blot. The FFC diet significantly increases mouse sEng levels and increases hepatic expression of Eng. High levels of human sEng results in increased hepatic deposition of cholesterol due to reduced conversion into BA, as well as redirects the metabolism of triglycerides (TAG) to its accumulation in the liver, via reduced TAG elimination by β-oxidation combined with reduced hepatic efflux. We propose that sEng might be a biomarker of NASH development, and the presence of high levels of sEng might support NASH aggravation by impairing the essential defensive mechanism protecting NASH liver against excessive TAG and cholesterol accumulation, suggesting the importance of high sEng levels in patients prone to develop NASH.

Biomedical Research Institute of Salamanca and Renal and Cardiovascular Physiopathology Unit Department of Physiology and Pharmacology University of Salamanca 370 06 Salamanca Spain

Centrum for Research and Development University Hospital Hradec Kralove 500 03 Hradec Kralove Czech Republic

Department of Biochemistry Faculty of Medicine in Hradec Kralove Charles University 500 03 Hradec Kralove Czech Republic

Department of Biological and Medical Sciences Faculty of Pharmacy in Hradec Kralove Charles University 500 05 Hradec Kralove Czech Republic

Department of Pharmacology Faculty of Medicine in Hradec Kralove Charles University 500 03 Hradec Kralove Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc21011839

003      

CZ-PrNML

005      

20210507102802.0

007      

ta

008      

210420s2020 sz f 000 0|eng||

009      

AR

024    7_

$a 10.3390/ijms21239021 $2 doi

035    __

$a (PubMed)33261044

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a sz

100    1_

$a Igreja Sá, Ivone Cristina $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic

245    10

$a Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver / $c IC. Igreja Sá, K. Tripska, M. Hroch, R. Hyspler, A. Ticha, H. Lastuvkova, J. Schreiberova, E. Dolezelova, S. Eissazadeh, B. Vitverova, I. Najmanova, M. Vasinova, M. Pericacho, S. Micuda, P. Nachtigal

520    9_

$a Nonalcoholic steatohepatitis (NASH) is characterized by hepatic steatosis with inflammation and fibrosis. Membrane endoglin (Eng) expression is shown to participate in fibrosis, and plasma concentrations of soluble endoglin (sEng) are increased in patients with hypercholesterolemia and type 2 diabetes mellitus. We hypothesize that NASH increases both hepatic Eng expression and sEng in blood and that high levels of sEng modulate cholesterol and bile acid (BA) metabolism and affect NASH progression. Three-month-old transgenic male mice overexpressing human sEng and their wild type littermates are fed for six months with either a high-saturated fat, high-fructose high-cholesterol (FFC) diet or a chow diet. Evaluation of NASH, Liquid chromatography-mass spectrometry (LC/MS) analysis of BA, hepatic expression of Eng, inflammation, fibrosis markers, enzymes and transporters involved in hepatic cholesterol and BA metabolism are assessed using Real-Time Quantitative Reverse Transcription Polymerase Chain reaction (qRT-PCR) and Western blot. The FFC diet significantly increases mouse sEng levels and increases hepatic expression of Eng. High levels of human sEng results in increased hepatic deposition of cholesterol due to reduced conversion into BA, as well as redirects the metabolism of triglycerides (TAG) to its accumulation in the liver, via reduced TAG elimination by β-oxidation combined with reduced hepatic efflux. We propose that sEng might be a biomarker of NASH development, and the presence of high levels of sEng might support NASH aggravation by impairing the essential defensive mechanism protecting NASH liver against excessive TAG and cholesterol accumulation, suggesting the importance of high sEng levels in patients prone to develop NASH.

650    _2

$a alkalická fosfatasa $x metabolismus $7 D000469

650    _2

$a zvířata $7 D000818

650    _2

$a aspartátaminotransferasy $x metabolismus $7 D001219

650    _2

$a biologické markery $x krev $x metabolismus $7 D015415

650    _2

$a cholesterol $x krev $x metabolismus $7 D002784

650    _2

$a dieta s vysokým obsahem tuků $7 D059305

650    _2

$a modely nemocí na zvířatech $7 D004195

650    _2

$a endoglin $x krev $x metabolismus $7 D000071063

650    _2

$a fruktosa $7 D005632

650    _2

$a lidé $7 D006801

650    _2

$a zánět $x patologie $7 D007249

650    _2

$a játra $x metabolismus $x patologie $7 D008099

650    _2

$a jaterní cirhóza $x krev $x komplikace $x patologie $7 D008103

650    _2

$a myši $7 D051379

650    _2

$a biologické modely $7 D008954

650    _2

$a nealkoholová steatóza jater $x krev $x komplikace $x metabolismus $7 D065626

650    _2

$a oxidační stres $7 D018384

650    _2

$a rozpustnost $7 D012995

650    _2

$a triglyceridy $x metabolismus $7 D014280

655    _2

$a časopisecké články $7 D016428

700    1_

$a Tripska, Katarina $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic

700    1_

$a Hroch, Milos $u Department of Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic

700    1_

$a Hyspler, Radomir $u Centrum for Research and Development University Hospital, Hradec Kralove, 500 03 Hradec Kralove, Czech Republic

700    1_

$a Ticha, Alena $u Centrum for Research and Development University Hospital, Hradec Kralove, 500 03 Hradec Kralove, Czech Republic

700    1_

$a Lastuvkova, Hana $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic

700    1_

$a Schreiberova, Jolana $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic

700    1_

$a Dolezelova, Eva $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic

700    1_

$a Eissazadeh, Samira $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic

700    1_

$a Vitverova, Barbora $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic

700    1_

$a Najmanova, Iveta $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic

700    1_

$a Vasinova, Martina $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic

700    1_

$a Pericacho, Miguel $u Biomedical Research Institute of Salamanca and Renal and Cardiovascular Physiopathology Unit, Department of Physiology and Pharmacology, University of Salamanca, 370 06 Salamanca, Spain

700    1_

$a Micuda, Stanislav $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic

700    1_

$a Nachtigal, Petr $u Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic

773    0_

$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 21, č. 23 (2020)

856    41

$u https://pubmed.ncbi.nlm.nih.gov/33261044 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20210420 $b ABA008

991    __

$a 20210507102801 $b ABA008

999    __

$a ok $b bmc $g 1650266 $s 1132218

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2020 $b 21 $c 23 $e 20201127 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142

GRA    __

$a 17-31754A $p Ministerstvo Zdravotnictví Ceské Republiky

GRA    __

$a CZ.02.1.01/0.0/0.0/16_019/0000841 $p Univerzita Karlova v Praze

GRA    __

$a 1166119 $p Grantová Agentura, Univerzita Karlova

GRA    __

$a SVV 260 549 $p Univerzita Karlova v Praze

GRA    __

$a NV17-31754A $p MZ0

LZP    __

$a Pubmed-20210420